Clinical Trial Search

Primary: Change in Wound Size From Baseline to Final Wound Evaluation up to 60 Days Later — -20.7; -13.9 cm^2

Primary: Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs) — 7; 3; 7; 3 Participants

Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 12 — -0.35; -0.60; -0.84; -0.73 percentage of A1C — p=0.07

Primary: Progression-free Survival (PFS) — 3.94; 4.39 Months

Primary: Quality of Life With NEI VFQ-25 — 82.9; 82.7; 82.8; 83.0 units on a scale

Primary: Procedure Duration — 6.8; 7.2 minutes

Primary: Number of Participants Who Redeemed FMNP Vouchers — 84; 77 participants

Primary: Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug — 0; 0; 0; 0 participants

Primary: Change From Baseline in Plasma HIV-1 RNA Copies Per mL at 168 Hours — -1.56; -1.76; -1.55; -1.78 log10 copies per mL

Primary: Frequency of Metabolizer Status (PM, IM, NM, UM) in Patients — 233; 22; 21; 11 Participants

Primary: Diagnostic Accuracy of "Three Rings Vulvoscopy" by the "Vulvoscopy Index" for Detection of Vulvar Dermatosis — 72; 0; 10; 246 Participants — p=0.6108

Primary: Number of Subjects Experiencing Tourniquet Hypertension — 5; 14 Participants

Primary: Percent Change From Baseline in Total Daily Bolus Amount of Exogenous Insulin Required Calculated Over Days 3 to 27 (Treatment Outpatient Period) — -46.32; -7.00; -32.14…

Primary: Healthy Eating Index 2010 Score — 71.30; 39.89 units on a scale

Primary: Metastasis-Free Survival — 40.37; 18.43 months — p=<0.000001